Objectives: The efficacy of abacavir/lamivudine has been reported to be inferior to tenofovir/emtricitabine. Several randomized clinical trials (RCTs) investigated the effectiveness and safety of abacavir/lamivudine and tenofovir/emtricitabine combined antiretroviral treatment (cART) and we have reviewed the available evidence.
Introduction
The current standard of care for HIV treatment is a three-drug regimen containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase strand transfer inhibitor plus two nucleoside/tide reverse transcriptase inhibitors (NRTIs).
1, 2 The most widely used NRTI backbones are available as fixed-dose coformulations that combine two drugs, tenofovir/emtricitabine or abacavir/lamivudine, in a single tablet taken once daily. Factors such as efficacy, lack of severe adverse events and patient convenience have led to tenofovir/emtricitabine and abacavir/lamivudine becoming the most widely prescribed initial backbones in industrialized countries. However, some divergences between European and US guidelines exist. While the European AIDS Clinical Society guidelines recommend tenofovir/emtricitabine or abacavir/lamivudine as the nucleoside backbone component of initial combination regimens, US guidelines recommend tenofovir/lamivudine as the first line and abacavir/lamivudine as an alternative regimen. However, in the 2014 updated US guidelines, in patients who are HLA-B*5701 negative abacavir/lamivudine + dolutegravir and, only for patients with baseline viral load (VL) value ,100000 copies/mL, abacavir/ lamivudine+ efavirenz, are among the preferred regimens. 1 Current guidelines assume lamivudine and emtricitabine to be equivalent. 1 Compared with lamivudine, emtricitabine shows a longer plasma and intracellular triphosphate half-life. The results of a recent meta-analysis of clinical trials comparing emtricitabine with lamivudine as part of a combination regimen have demonstrated that the two compounds are clinically equivalent. 3 Thus, in clinical practice the choice of emtricitabine versus lamivudine will most likely be made in the context of their coformulation partner.
Differences between abacavir and tenofovir are of more interest. While tenofovir has few initial treatment-limiting initial side effects, older studies with abacavir are difficult to interpret due to the excess of abacavir hypersensitivity reactions, which lead to early discontinuation and hence an excess of 'failure' in intention-totreat analysis. The establishment of HLA-B*5701 testing has largely led to the abolition of this adverse effect from clinical practice. Recent data have offered conflicting evidence concerning the relative efficacy of NRTI backbone combinations. A randomized controlled trial (ACTG 5202) showed that among patients with a high VL at study entry (screening) (HIV RNA .100000 copies/mL), those taking abacavir/lamivudine with either boosted atazanavir or efavirenz were more likely to experience virological failure than those taking tenofovir/emtricitabine. 4 By contrast, a randomized clinical trial (RCT) with a head-to-head comparison of abacavir/lamivudine with tenofovir/emtricitabine, in combination with lopinavir/ritonavir, and a retrospective analysis of six previous abacavir trials found that the backbones had similar efficacy. 5, 6 Of note, all these studies did not employ routine HLA-B*5701 screening and the ACTG 5202 study used endpoints and analyses that differed from the other studies.
Numerous RCTs have been conducted to assess the effectiveness and safety of abacavir-and tenofovir-containing combined antiretroviral treatment (cART). Recently, two meta-analyses on the safety of abacavir have been published. 7, 8 However, these reviews were mostly focused on cardiovascular complications of cART. The current review is therefore aimed to shed more light on the effectiveness of abacavir-containing cART.
Methods

Criteria for considering studies for this review
We included in the analysis any RCTs in HIV-infected adults (starting a first antiretroviral regimen as well as antiretroviral-experienced participants) with ≥24 weeks of abacavir exposure compared with other cART regimens. cART taken while in the studies was categorized as abacavir-containing or non-abacavir-containing. Exposure to any possible formulation of abacavir was considered, including double (abacavir +lamivudine) and triple (abacavir +lamivudine+zidovudine) fixed-dose coformulation as well as both once-and twice-daily dosing.
Outcomes
Primary outcomes were rates of patients with VL below the pre-defined cut-off (,50 copies/mL and/or 200 -500 copies/mL) at 48 weeks and/or at 96 weeks.
Where available, we reported the results for this endpoint according to VL screening levels (,100 000 or .100 000 copies/mL) and according to the missing ¼ failure approach (assigning anyone who has to stop the drug of interest as having failed), the 'time to loss of virological response' (TLOVR) algorithm (a composite of all available safety and antiviral activity data from all subjects enrolled in a trial through 48 weeks of treatment) or the 'snapshot' approach, not affected by transitional changes in HIV levels. A high concordance between the TLOVR algorithm and snapshot results was observed. 9 Secondary outcomes were rates of patients with adverse events requiring treatment interruption and/or switching.
Search methods for identification of studies
We updated (June 2014) the search conducted for a previous metaanalysis. 7 The search included the following relevant MeSH terms, in various combinations: highly active antiretroviral therapy; antiretroviral agents; abacavir; abacavir/lamivudine combination; Trizivir; Kivexa; Epzicom; tenofovir; randomized controlled trial, controlled trial; adverse effects, resistance, treatment outcome, treatment failure.
The Hand searches of the reference lists of all the relevant reviews and studies found was undertaken. Information about trials not registered in MEDLINE, including unpublished ones, was attempted by contacting drug manufacturers for repository data and scanning reference lists of articles.
Data collection and extraction
Two authors (M. C. and C. M.) independently screened for potential relevance the titles and abstracts of references identified by the search. Disagreement or doubt was resolved by discussion. We obtained in full any study that potentially met the inclusion criteria based on the title, abstract or both and assessed these studies against the inclusion criteria.
The following data were extracted independently by two reviewers (M. C. and C. M.): administrative details (authors and year of publication); details of participants (number, setting and baseline characteristics by group); details of the study (study design, type and duration of follow-up); details of the ART regimen used; primary and secondary outcome descriptions and outcome measures; and number of withdrawals in each group with reasons.
The data abstracted for dichotomous variables were the number of affected participants and the total number of participants in the experimental and the comparison groups. When additional data were needed, we contacted the corresponding author of each study by e-mail in order to access further information.
Assessment of risk of bias in included studies
Two authors (M. C. and M. M.) independently assessed studies fulfilling the review inclusion criteria for methodological quality given in the Cochrane Handbook for Systematic Reviews of Interventions. 10 The risk of bias was assessed in individual studies across six domains: random sequence generation; allocation concealment; blinding of participants and personnel (performance bias); blinding of outcome assessors (detection bias); incomplete outcome data; and selective outcome reporting. We categorized these judgements as 'low risk', 'high risk' or 'unclear risk' of bias.
Assessment of heterogeneity
We assessed statistical heterogeneity using t 2 , Cochran's Q and I 2 statistics. The I 2 statistic describes the percentage of total variation across trials that is due to heterogeneity rather than sampling error.
11,12
Data synthesis
Dichotomous outcomes (e.g. rate of patients with virological suppression) are presented as risk ratios (RRs) with 95% CIs. The software used was RevMan5. In the case of no heterogeneity (I 2 ¼ 0), studies were pooled using a fixed-effects model. Where values of I 2 were .0, a random-effects Systematic review analysis was undertaken. 10, 13 Where I 2 values of .75% indicated a very high level of heterogeneity, we refrained to pool data from different studies and we undertook a narrative overview.
Subgroup and sensitivity analyses
Since fixed-dose coformulations of abacavir/lamivudine and tenofovir/ emtricitabine are currently the most widely prescribed NRTI backbone, we performed subgroup analysis of studies with a head-to-head comparison of abacavir/lamivudine and tenofovir/emtricitabine and a separate analysis of studies comparing abacavir-containing regimens with other cART regimens (i.e. those not containing tenofovir). We also performed subgroup analyses according to relevant study-level variables: studies dealing with naive patients; studies dealing with experienced patients; studies with baseline VL ,100 000 copies/mL; and studies with baseline VL .100000 copies/mL. Finally, we performed a subgroup analysis after exclusion of data available from repository data only.
A sensitivity analysis was performed systemically excluding each study in turn, in both the standard meta-analytical pooling and meta-regression.
Meta-regression
A comparison between studies with baseline plasma HIV viraemia ,100 000 copies/mL and studies with baseline VL .100 000 copies/mL was performed on a subset of studies comparing an experimental treatment (abacavir) with a control treatment (tenofovir). For this purpose, we used meta-regression, which allows a direct comparison between the two subgroups. The null hypothesis is that the baseline VL in the experimental treatment does not alter the treatment effect. The effect size under comparison was the rate ratio for events (VL,cut-off) between the experimental arm and the control arm. The method was the residual maximum likelihood estimate of between-study variance. The dependent variable was the RR obtained from conventional meta-analytical pooling and the explanatory variable was the baseline VL. Meta-regression was performed using Stata 12.
Results
Electronic searches yielded 1471 potentially relevant studies ( Figure 1 ). Some 1430 articles were excluded after preliminary screen and 41 were deemed eligible and the full-text assessed. Eleven studies were then excluded because they were not randomized or did not report outcomes of interest; 13 additional records were available through the HIV Clinical Trial data repository of the manufacturer of abacavir. Therefore, we included in the analysis data from 43 reports, including 30 published articles (29 full-length papers and 1 abstract) related to RCTs conducted from 1996 to 2013, comparing cART containing abacavir with cART containing other NRTIs. 4,5,14 -41 When outcome data were available both from published and non-published reports, we extracted data from the published material only; likewise, for these studies we counted the total number of patients from the published papers only. Two trials were not randomized for abacavir/lamivudine and tenofovir/emtricitabine assignment, though randomization for the third drug was stratified based on the NRTI backbone, and there were no systematic differences between the baseline characteristics of the two NRTI groups compared. 34, 35, 38 The main features of the included studies are summarized in Table 1 . Table 2 summarizes the pooled outcome data and heterogeneity assessment (I 2 ) for the outcomes in overall analyses and subgroup analyses. Figure 2 shows forest plots of the RR and 95% CI for individual studies and pooled estimates of the meta-analysis for the outcomes 'rates of patients with VL ,50 copies/mL at 48 and 96 weeks'. Rates were similar among abacavir recipients and controls in all possible comparisons.
Rates of patients requiring discontinuation of treatment due to adverse events related to study treatment are shown in Table 2 and Figure 3 . In the comparison of abacavir-versus nontenofovir-containing regimens, the rate of discontinuation was lower in the abacavir group compared with controls (P¼0.0001); however, in the subgroup of studies comparing abacavir-versus tenofovir-containing regimens the RR of discontinuation favoured tenofovir, though this difference did not reach statistical significance (RR 1.26; 95% CI 0.99-1.61; P¼0.06). 
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) with an updating of BICOMBO data. d SPRING 2 and FLAMINGO 34, 35, 38 were not randomized for ABC and TDF assignment, though randomization for the third drug was stratified based on baseline VL and NRTI backbone. e Median age is 37 years for the dolutegravir recipients and 35 years for the raltegravir recipients. There was a very high level of heterogeneity (I 2 .75%) for the outcome 'rates of patients with HIV ,200 -500 copies/mL at 48 weeks', and for the subgroup of studies abacavir versus other, for the outcome 'rates of patients with HIV ,50 copies/mL at 96 weeks'; for these outcomes we did not perform a quantitative analysis of data. Rates of patients with HIV ,200-500 copies/mL at 96 weeks are shown in Table S1 and Figure S1 (both available as Supplementary data at JAC Online).
Subgroup analyses in Table 2 , Figures 2 and 4 show the outcome data for the subgroup of studies (11 studies and 15 reports) from where a direct comparison between abacavir/lamivudine and tenofovir/emtricitabine was available. 4,5,26,29 -39,41 Overall, the virological outcomes did not differ between the two groups. There were a higher number of adverse events requiring discontinuation of treatment among abacavir recipients compared with tenofovir recipients, but the difference was not statistically significant.
Subgroup analysis of studies conducted in naive patients and in experienced patients did not significantly affect the pooled estimates of the meta-analysis (data not shown). Likewise, the results were much the same in subgroup analysis of studies after the exclusion of repository data (data not shown).
Subgroup analysis of studies comparing abacavir and tenofovir according to baseline viraemia
Data from the nine reports (eight trials) with a head-to-head comparison of abacavir and tenofovir and subgroup analysis according to baseline VL values (,100 000 or .100 000 copies/mL) were pooled. 4,5,33 -39 The proportions of subjects with VL ,50 copies/mL at 48 and 96 weeks are shown in Figure 4 . At week 48, rates were similar among abacavir and tenofovir in the overall comparison (RR 0.98; 95% CI 0.94 -1.03), in the high baseline VL strata (RR 0.96; 95% CI 0.90-1.03) and in the low VL strata (RR 1.01; 95% CI 0.99-1.04). Likewise, at week 96, rates of patients with undetectable VL were comparable in the abacavir and tenofovir groups, regardless of the baseline VL (RR 0.98, 95% CI 0.93 -1.03 in the overall comparison; RR 0.97, 95% CI 0.87 -1.08 in the high baseline VL strata; and RR 0.99, 95% CI 0.93-1.04 in the low VL strata).
Meta-regression
By meta-regression, the null hypothesis of the same virological effect exerted by abacavir/lamivudine and tenofovir/emtricitabine Systematic review at 48 weeks was never rejected ( Figure 5 ). The meta-regression analysis reported an RR of abacavir producing a different success rate with respect to tenofovir with a VL .100000 copies/mL not significantly different from the null hypothesis of 1 (RR 0.95; 95% CI 0.89 -1.02; P ¼ 0.165) (Table S1 ). Due to the small number of studies at 96 weeks, the meta-regression was limited at 48 weeks.
Sensitivity analysis
After exclusion of an individual study in turn, the summary estimates were not affected in the overall comparison and in subgroup analysis of studies with baseline VL ,100 000 copies/mL (Table S2, Table S3 and Table S4 , all available as Supplementary data at JAC Online). However, in the subgroup of studies with VL .100 000 copies/mL, the overall estimates, in both standard meta-analytical pooling and meta-regression, changed after exclusion of the study by Raffi et al.:
34 RR favouring tenofovir, 0.92 (95% CI 0.86 -0.98) and 0.91 (95% CI 0.84-0.98), respectively (Table S3 and Table S4 ).
Bias assessment and heterogeneity
Summary graphs of methodological quality items are presented in Figure S2 and Figure S3 (both available as Supplementary data at JAC Online) for 41 reports, corresponding to 29 primary trials, but not for the meta-analysis of BICOMBO and STEAL data. 31 The generation of the randomization process was clearly described in 62% (18/29) of trials and was unclear in the other trials. Allocation concealment was adequately described in 37% of trials. There were 10 placebo-controlled trials and 19 openlabel trials. The remaining items were graded as free of bias in Systematic review 3175 JAC all trials but one: a repository study (NZTA4002) from which it was not possible to have clear information on some quality items.
Heterogeneity data (t 2 , x 2 and I 2 ) are reported in the footnotes to the forest plots. Substantial heterogeneity (e.g. I 2 .50%) was found for some of the virological outcomes.
Discussion
Controversy about the relative performance of abacavir/lamivudine and tenofovir/emtricitabine in combination antiretroviral therapy exists and recent clinical trials and reviews have raised concerns about each combination's relative risks and benefits. In a comparative safety study of abacavir/lamivudine and tenofovir/emtricitabine, differences in tubular protein loss, bone turnover markers and declines in bone density were observed favouring abacavir/lamivudine. 37 A number of reports have linked renal tubular dysfunction and acute renal failure with tenofovir; moreover, modest decreases in bone density and hypophosphataemia have been observed among tenofovir recipients. 1 An association between cART and the risk of myocardial infarction has been observed in some cohort studies, 42 -45 but not in other observational studies. 46 -48 Moreover, no excess risk of myocardial infarction with abacavir therapy has been observed in the aggregated clinical trials database maintained by the manufacturer of abacavir and in two independent meta-analyses comparing abacavir-containing cART with other regimens not containing abacavir. 7, 8, 49 The majority of studies conducted in the absence of confounding factors have not demonstrated an increased abacavir-attributable cardiovascular risk. To date, many hypotheses and in vitro data investigating biological mechanisms to explain a potential increase in the risk of cardiovascular diseases in abacavir recipients have been produced, but the topic remains controversial and none of the hypotheses has been established or clinically proven. 50 Treatment with cART improves endothelial dysfunction, but data on abacavir use and endothelial function are limited to small cohort studies. 51, 52 Results from other studies failed to demonstrate specific abnormalities in coagulation or inflammation markers that might explain the increased risk of myocardial infarction in abacavir recipients. 5,33,53 -55 On the basis Systematic review of these findings, abacavir/lamivudine has been repositioned as an 'alternative' dual fixed-dose NRTI option for the treatment of naive HIV-infected patients in the US Department of Health and Human Services HIV treatment guidelines and in the International AIDS Society-USA HIV treatment guidelines. 1, 56 Nonetheless, abacavir/lamivudine continues to be a 'preferred' option in international and European guidelines. 2, 57 At present, perhaps more relevant are issues related to the comparative efficacy of abacavir and tenofovir fixed-dose combinations. The efficacy of abacavir in viral suppression has been reported to be inferior to tenofovir among patients with baseline HIV VL .100000 copies/mL: results of the ACTG 5202 study showed that among patients with baseline HIV RNA ≥100000 copies/mL, time to virological failure was significantly shorter and the rate of virological failure higher for the abacavir/lamivudine recipients. 4, 39 Subsequently, guidelines have started to recommend caution in the use of abacavir in patients with high pre-treatment HIV RNA levels. 1, 2 Given that a variety of RCTs have been conducted to assess the effectiveness and safety of abacavir-containing cART, we have performed a systematic review and meta-analysis of RCTs to assess the virological efficacy of cART containing abacavir relative to abacavir-sparing cART. Moreover, a subgroup comparison has been performed in studies comparing cART containing abacavir relative to cART containing tenofovir.
Bias assessment using Cochrane methodology showed that the studies analysed had few methodological limitations. Although the generation of randomization process and allocation concealment were often not adequately described, there were no systematic differences between the baseline characteristics of the groups that were compared in individual studies. Only one-third of included studies were blind. However, the primary outcome of the analysis and its measurement (VL) are not likely to be influenced by lack of blinding; on the other hand, blinding could have been important for assessment of subjective outcomes such as interruption of treatment for adverse events, namely hypersensitivity reactions.
Our quantitative findings suggest that virological outcomes did not differ between abacavir-containing and -non-containing cART, both in the overall comparison and in the comparison with tenofovir-containing cART. Differences in the occurrence of adverse events requiring discontinuation of treatment favoured tenofovir recipients, but not in a statistically significant manner. In some of the included studies, this difference was driven by abacavir discontinuation due to suspected hypersensitivity reaction and HLA-B*5701 screening for hypersensitivity reaction was required in only two trials, 30, 37 while in the ACTG 5202 study the test was permitted but not required. In the remaining studies, HLA-B*5701 screening was not performed and in some of these trials (e.g. the BICOMBO and HEAT studies) the difference in JAC treatment efficacy was mostly related to abacavir discontinuation due to suspected hypersensitivity reaction. In a study from Japan, screening was permitted but not required due to the low prevalence of the HLA-B*5701 allele in the Japanese population. 36,58 -60 At present, when HLA-B*5701 screening is not readily available, it remains reasonable to initiate abacavir with appropriate clinical counselling and monitoring for any signs of hypersensitivity reaction. 1 Meta-analytical pooling of studies with a head-to-head comparison of abacavir and tenofovir and subgroup analysis according to baseline VL values (,100 000 or .100 000 copies/mL) showed that the proportions of subjects with VL below the cut-off of detectability at 48 and 96 weeks were similar among abacavir and tenofovir in the overall comparison, in the high baseline VL strata and the low VL strata. In addition, meta-regression analysis at 48 weeks confirms the results of meta-analytical pooling by subgroups, not supporting a rejection of the null hypothesis of abacavir producing a different success rate with respect to tenofovir with a VL .100 000 copies/mL. In other words, the baseline VL does not appear to affect the virological efficacy of abacavir. In sensitivity analysis, exclusion of any one study had a small effect on the pooled RR estimate, but exclusion of the study by Raffi et al. 34 from the subgroup analysis of high baseline viraemia studies had influence on the cumulative results, leading to an RR favouring tenofovir. This is not surprising considering that this study has a large sample size (495 patients) and, based on the inverse of variance, the highest meta-analytical weight (38%) in the subgroup of studies with high baseline viraemia.
Our findings of similar virological efficacy according to NRTI backbone regardless of the baseline VL contrast with those of the ACTG 5202 trial. In the ACTG 5202 study, the time to virological failure was significantly shorter and the rate of virological failure higher for the abacavir/lamivudine recipients. The discordance with our findings and those seen in the ACTG 5202 study can be partially related to the specific endpoints (week 16 definitions of viral failure, plus later ones) used in this study but not in other studies. Furthermore, once subjects were suppressed in the ACTG 5202 on abacavir-based therapy they maintained suppression, and in 'as treated' analysis rates of suppression were similar in the two arms. This suggests an anomaly arising from the early endpoint definitions in ACTG 5202 over classifying abacavir recipients as failures. Our analysis shows that the rate of virological failure is not higher in abacavir recipients compared with tenofovir recipients, regardless of baseline VL. However, our estimates are based on cross-sectional data and it was not possible, from the available evidence, to perform a time-to-event meta-analysis. Nevertheless, no differences in time to virological failure were observed in a large Canadian cohort of HIV-infected individuals. 61 The time to regimen failure was similar for abacavir/lamivudine and tenofovir/emtricitabine even when stratified by baseline VL (,100 000 or .100 000 copies/mL). These results support the use of abacavir/lamivudine as one of the 'preferred' NRTI options. Figure 5 . Meta-regression of virological efficacy at 48 weeks in studies comparing abacavir-containing cART with tenofovir-containing cART according to baseline VL. On the y-axis the natural logarithm (ln) of the risk ratio (RR) is given. The baseline viraemia is given on the x-axis: VL¼0 (,100000 copies/mL) and VL¼1 (.100000 copies/mL). The circles indicate the studies and the line of the mean represents the VL effect on ln(RR). There was a large overlap between the 95% CIs at VL ¼0 and VL¼1.
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